Christopher Paul Eckstein
Division Chief, Neuroimmunology and Multiple Sclerosis; Director, Residency Program
Associate Professor of Neurology
Email address:
christopher.eckstein@duke.edu
Education and Training
- M.D., University of Alabama School of Medicine, 2005
Selected Grants and Awards
- A prospective, multicenter, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in
patients with relapsing forms of multiple sclerosis (PASS) - A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
- Deciphering the role of noncoding variation in the pathogenesis of multiple sclerosis
- MS Clinical Trial: DUOC
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and
Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies - PA Fellowship in Clinical Neuroimmunology
- A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients with Relapsing Neuromyelitis Optica